TACE 联合靶向或免疫药物治疗中晚期肝细胞癌的研究进展
摘要
胆管癌（cHCC-CCA）三种不同病理学类型，其中 HCC 占 75%~85%，最为多见。HCC 的全球发病率上升和死亡率居高
不下，要求我们采取紧急和创新的措施来改善患者的预后。随着近些年靶免治疗的兴起，通过治疗方式的改进，较大程度
降低了 HCC 患者死亡率，并改善了患者生活质量。在本综述中，我们论述了 TACE 联合靶向以及 TACE 联合免疫治疗中
晚期 HCC 的最新研究成果，涵盖了联合治疗策略的临床证据，以及探索了未来 TACE 联合治疗在未来为肝癌患者提供个
性化的综合治疗方案，提高患者生存期的潜力。
关键词
全文:
PDF参考
[1] Sung H, Ferlay J, Siegel R L, et al. Global Cancer
Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality
Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J
Clin,2021,71(3):209-249.
[2] Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J].
Lancet,2018,391(10127):1301-1314.
[3] EASL Clinical Practice Guidelines: Management of
hepatocellular carcinoma[J]. J Hepatol,2018,69(1):182-236.
[4] 中华人民共和国国家卫生健康委员会 . 原发性肝癌
诊疗指南 (2024 年版 )[J]. 临床肝胆病杂志 ,2024,40(5):893-918.
[5] Wang B, Xu H, Gao Z Q, et al. Increased expression of
vascular endothelial growth factor in hepatocellular carcinoma
after transcatheter arterial chemoembolization[J]. Acta
Radiol,2008,49(5):523-529.
[6] Liu Y, Cao X. Immunosuppressive cells in tumor immune
escape and metastasis[J]. J Mol Med (Berl),2016,94(5):509-522.
[7] Yap T A, Parkes E E, Peng W, et al. Development of
Immunotherapy Combination Strategies in Cancer[J]. Cancer
Discov,2021,11(6):1368-1397.
[8] EASL-EORTC clinical practice guidelines: management
of hepatocellular carcinoma[J]. J Hepatol,2012,56(4):908-943.
[9] Llovet J M, Bruix J. Systematic review of randomized trials
for unresectable hepatocellular carcinoma: Chemoembolization
improves survival[J]. Hepatology,2003,37(2):429-442.
[10] Han G, Berhane S, Toyoda H, et al. Prediction of Survival
Among Patients Receiving Transarterial Chemoembolization for
Hepatocellular Carcinoma: A Response-Based Approach[J].
Hepatology,2020,72(1):198-212.
[11] Schicho A, Hellerbrand C, Kruger K, et al.
Impact of Different Embolic Agents for Transarterial
Chemoembolization (TACE) Procedures on Systemic Vascular
Endothelial Growth Factor (VEGF) Levels[J]. J Clin Transl
Hepatol,2016,4(4):288-292.
[12] Greten T F, Korangy F, Manns M P, et al. Molecular
therapy for the treatment of hepatocellular carcinoma[J]. Br J
Cancer,2009,100(1):19-23.
[13] Koch C, Goller M, Schott E, et al. Combination of
Sorafenib and Transarterial Chemoembolization in Selected
Patients with Advanced-Stage Hepatocellular Carcinoma: A
Retrospective Cohort Study at Three German Liver Centers[J].
Cancers (Basel),2021,13(9).
[14] Zhao Y, Wang W J, Guan S, et al. Sorafenib combined
with transarterial chemoembolization for the treatment of
advanced hepatocellular carcinoma: a large-scale multicenter
study of 222 patients[J]. Ann Oncol,2013,24(7):1786-1792.
[15] Kawamura Y, Kobayashi M, Shindoh J, et al.
Lenvatinib-Transarterial Chemoembolization Sequential Therapy
as an Effective Treatment at Progression during Lenvatinib
Therapy for Advanced Hepatocellular Carcinoma[J]. Liver
Cancer,2020,9(6):756-770.
[16] Liu K C, Hao Y H, Lv W F, et al. Transarterial
Chemoembolization Combined with Sorafenib in Patients with
BCLC Stage C Hepatocellular Carcinoma[J]. Drug Des Devel
Ther,2020,14:3461-3468.
[ 1 7 ] L e e S W , L e e T Y , P e n g Y C , e t a l . T h e
therapeutic benefits of combined sorafenib and transarterial
chemoembolization for advanced hepatocellular carcinoma[J]. J
Dig Dis,2020,21(5):287-292.
[18] Varghese J, Kedarisetty C, Venkataraman J, et al.
Combination of TACE and Sorafenib Improves Outcomes in
BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre
Experience[J]. Ann Hepatol,2017,16(2):247-254.
[19] Kudo M, Ueshima K, Ikeda M, et al. Randomised,
multicentre prospective trial of transarterial chemoembolisation
(TACE) plus sorafenib as compared with TACE alone in
patients with hepatocellular carcinoma: TACTICS trial[J].
Gut,2020,69(8):1492-1501.
[20] Chen R, Li L, Li Y, et al. Efficacy and safety of
transcatheter arterial chemoembolization-lenvatinib sequential
therapy for patients with unresectable hepatocellular
carcinoma: a single-arm clinical study[J]. J Gastrointest
Oncol,2022,13(3):1367-1375.
[21] Cheon J, Chon H J, Bang Y, et al. Real-World Efficacy
and Safety of Lenvatinib in Korean Patients with Advanced
Hepatocellular Carcinoma: A Multicenter Retrospective
Analysis[J]. Liver Cancer,2020,9(5):613-624.
[22] Peng Z, Fan W, Zhu B, et al. Lenvatinib Combined With
Transarterial Chemoembolization as First-Line Treatment for
Advanced Hepatocellular Carcinoma: A Phase III, Randomized
Clinical Trial (LAUNCH)[J]. J Clin Oncol,2023,41(1):117-127.
[23] Matsuda N, Imai N, Kuzuya T, et al. Progression
After Molecular Targeted Agents: Hepatic Arterial Changes and
Transarterial Chemoembolization in Hepatocellular Carcinoma[J].
In Vivo,2021,35(2):1185-1189.
[24] Rimassa L, Pressiani T, Personeni N, et al. Regorafenib
for the treatment of unresectable hepatocellular carcinoma[J].
Expert Rev Anticancer Ther,2017,17(7):567-576.
[25] Mross K, Frost A, Steinbild S, et al. A phase I dose-
escalation study of regorafenib (BAY 73-4506), an inhibitor
of oncogenic, angiogenic, and stromal kinases, in patients with
advanced solid tumors[J]. Clin Cancer Res,2012,18(9):2658-
2667.
[26] Choi G H, Shim J H, Kim M J, et al. Sorafenib alone
versus sorafenib combined with transarterial chemoembolization
for advanced-stage hepatocellular carcinoma: results of propensity
score analyses[J]. Radiology,2013,269(2):603-611.
[27] Wang H, Xiao W, Han Y, et al. Study on safety and
efficacy of regorafenib combined with transcatheter arterial
chemoembolization in the treatment of advanced hepatocellular
carcinoma after first-line targeted therapy[J]. J Gastrointest
Oncol,2022,13(3):1248-1254.
[28] Bao Y, Feng W M, Tang C W, et al. Endostatin
inhibits angiogenesis in hepatocellular carcinoma after
transarterial chemoembolization[J]. Hepatogastroenterolo
gy,2012,59(117):1566-1568.
[29] Wei F, Zhong S, Ma Z, et al. Strength of PD-1 signaling
differentially affects T-cell effector functions[J]. Proc Natl Acad
Sci U S A,2013,110(27):E2480-E2489.
[30] Strome S E, Dong H, Tamura H, et al. B7-H1 blockade
augments adoptive T-cell immunotherapy for squamous cell
carcinoma[J]. Cancer Res,2003,63(19):6501-6505.
[31] Bai J, Liang P, Li Q, et al. Cancer Immunotherapy -
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma[J].
Recent Pat Anticancer Drug Discov,2021,16(2):239-248.
[32] Whiteside T L, Demaria S, Rodriguez-Ruiz M
E, et al. Emerging Opportunities and Challenges in Cancer
Immunotherapy[J]. Clin Cancer Res,2016,22(8):1845-1855.
[33] Weber J S, D’Angelo S P, Minor D, et al. Nivolumab
versus chemotherapy in patients with advanced melanoma who
progressed after anti-CTLA-4 treatment (CheckMate 037): a
randomised, controlled, open-label, phase 3 trial[J]. Lancet
Oncol,2015,16(4):375-384.
[34] Motzer R J, Escudier B, Mcdermott D F, et al. Nivolumab
versus Everolimus in Advanced Renal-Cell Carcinoma[J]. N Engl
J Med,2015,373(19):1803-1813.
[35] Topalian S L, Drake C G, Pardoll D M. Immune
checkpoint blockade: a common denominator approach to cancer
therapy[J]. Cancer Cell,2015,27(4):450-461.
[36] Prieto J, Melero I, Sangro B. Immunological landscape
and immunotherapy of hepatocellular carcinoma[J]. Nat Rev
Gastroenterol Hepatol,2015,12(12):681-700.
[37] Flecken T, Schmidt N, Hild S, et al. Immunodominance
and functional alterations of tumor-associated antigen-specific
CD8+ T-cell responses in hepatocellular carcinoma[J]. Hepatolo
gy,2014,59(4):1415-1426.
[38] Shi F, Shi M, Zeng Z, et al. PD-1 and PD-L1
upregulation promotes CD8(+) T-cell apoptosis and postoperative
recurrence in hepatocellular carcinoma patients[J]. Int J
Cancer,2011,128(4):887-896.
[39] Breous E, Thimme R. Potential of immunotherapy for
hepatocellular carcinoma[J]. J Hepatol,2011,54(4):830-834.
[40] Llovet J M, Vogel A, Madoff D C, et al. Randomized
Phase 3 LEAP-012 Study: Transarterial Chemoembolization With
or Without Lenvatinib Plus Pembrolizumab for Intermediate-
Stage Hepatocellular Carcinoma Not Amenable to Curative
Treatment[J]. Cardiovasc Intervent Radiol,2022,45(4):405-412.
[41] Finn R S, Ikeda M, Zhu A X, et al. Phase Ib
Study of Lenvatinib Plus Pembrolizumab in Patients
With Unresectable Hepatocellular Carcinoma[J]. J Clin
Oncol,2020,38(26):2960-2970.
[42] Llovet J M, De Baere T, Kulik L, et al. Locoregional
therapies in the era of molecular and immune treatments
for hepatocellular carcinoma[J]. Nat Rev Gastroenterol
Hepatol,2021,18(5):293-313.
[43] Liu L, Zhang R, Deng J, et al. Construction of TME
and Identification of crosstalk between malignant cells and
macrophages by SPP1 in hepatocellular carcinoma[J]. Cancer
Immunol Immunother,2022,71(1):121-136.
[44] Liu Y, Xun Z, Ma K, et al. Identification of a tumour
immune barrier in the HCC microenvironment that determines the
efficacy of immunotherapy[J]. J Hepatol,2023,78(4):770-782.
[45] Yamauchi R, Ito T, Yoshio S, et al. Serum osteopontin
predicts the response to atezolizumab plus bevacizumab
in patients with hepatocellular carcinoma[J]. J Gastroenter
ol,2023,58(6):565-574.
[46] Pinato D J, Murray S M, Forner A, et al. Trans-arterial
chemoembolization as a loco-regional inducer of immunogenic
cell death in hepatocellular carcinoma: implications for
immunotherapy[J]. J Immunother Cancer,2021,9(9).
[47] Cheng Y, Spigel D R, Cho B C, et al. Durvalumab after
Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer[J].
N Engl J Med,2024,391(14):1313-1327.
[48] Riccardo Lencioni et al., EMERALD-1: A phase
3, randomized, placebo-controlled study of transarterial
chemoembolization combined with durvalumab with or without
bevacizumab in participants with unresectable hepatocellular
carcinoma eligible for embolization.. JCO 42, LBA432-
LBA432(2024).
[49] 姜楠，黄金涛，聂宏，等 . TACE 联合靶向免疫药
物治疗晚期肝细胞癌的有效性和安全性 [J]. 介入放射学杂
志 ,2023,32(5):441-445.
[50]Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J,
Chen Y, Zenke Y, Lee KH, Wang Q, Navarro A, Bernabe R,
Buchmeier EL, Chang JW, Shiraishi Y, Goksu SS, Badzio A,
Shi A, Daniel DB, Hoa NTT, Zemanova M, Mann H, Gowda H,
Jiang H, Senan S; ADRIATIC Investigators. Durvalumab after
Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. N
Engl J Med. 2024 Oct 10;391(14):1313-1327.
(3 摘要 Views, 2 PDF Downloads)
Refbacks
- 当前没有refback。